Skip Nav Destination
How I treat atypical chronic myeloid leukemia
Free
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Free
Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations
Free
Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis
Free
Issue Archive
February 16 2017
In this Issue
Table of Contents
INSIDE BLOOD COMMENTARIES
PERSPECTIVE
REVIEW ARTICLE
EVIDENCE-BASED FOCUSED REVIEW
HOW I TREAT
How I treat atypical chronic myeloid leukemia
Free
Clinical Trials & Observations
CLINICAL TRIALS AND OBSERVATIONS
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Free
Clinical Trials & Observations
Delphine Rea,Franck E. Nicolini,Michel Tulliez,François Guilhot,Joelle Guilhot,Agnès Guerci-Bresler,Martine Gardembas,Valérie Coiteux,Gaelle Guillerm,Laurence Legros,Gabriel Etienne,Jean-Michel Pignon,Bruno Villemagne,Martine Escoffre-Barbe,Jean-Christophe Ianotto,Aude Charbonnier,Hyacinthe Johnson-Ansah,Marie-Pierre Noel,Philippe Rousselot,François-Xavier Mahon,for the France Intergroupe des Leucémies Myéloïdes Chroniques
IMMUNOBIOLOGY
iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease Free
Zineb Sbihi,Antoine Dossier,David Boutboul,Lionel Galicier,Christophe Parizot,Amandine Emarre,Bénédicte Hoareau,Nicolas Dupin,Anne-Geneviève Marcelin,Anne Oudin,Claire Fieschi,Félix Agbalika,Brigitte Autran,Eric Oksenhendler,Guislaine Carcelain
LYMPHOID NEOPLASIA
EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia–like B-cell malignancies Free
Kristine Niss Arfelt,Line Barington,Tau Benned-Jensen,Valentina Kubale,Alexander L. Kovalchuk,Viktorija Daugvilaite,Jan Pravsgaard Christensen,Allan Randrup Thomsen,Kristoffer L. Egerod,Maria R. Bassi,Katja Spiess,Thue W. Schwartz,Hongsheng Wang,Herbert C. Morse, III,Peter J. Holst,Mette M. Rosenkilde
MYELOID NEOPLASIA
Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations
Free
Clinical Trials & Observations
Brief Report
Thierry M. Nordmann,Freimut D. Juengling,Mike Recher,Christoph T. Berger,Daniel Kalbermatten,Andreas Wicki,Aino Paasinen-Sohns,Gieri Cathomas,Alexandar Tzankov,Thomas Daikeler
PLATELETS AND THROMBOPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis
Free
Clinical Trials & Observations
Ryan H. Moy,Austin P. Huffman,Lee P. Richman,Lisa Crisalli,Ximi K. Wang,James A. Hoxie,Rosemarie Mick,Stephen G. Emerson,Yi Zhang,Robert H. Vonderheide,David L. Porter,Ran Reshef
BLOOD WORK
ERRATUM
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
Expression of the CD30 receptor by human CD4+ T lymphocytes virally transduced to express the highly oncogenic tyrosine kinase NPM-ALK. CD30 expression was visualized in tumors formed by these transformed lymphocytes in nonobese diabetic/severe combined immunodeficient γ mice by immunohistochemistry. See the article by Werner et al on page 823.
- PDF Icon Front MatterFront Matter
- PDF Icon Table of ContentsTable of Contents
- PDF Icon Back MatterBack Matter
- PDF Icon Editorial BoardEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals